KRAS and colorectal carcinoma: Inhibition of the MAPK pathway showed no clinical benefit in KRAS-mutant CRC, unless it was coupled with the suppression of IFN-stimulated gene (ISG) expression (Figure 5), leading to cancer cells apoptosis [110].